Chargement en cours...
Ceftolozane–tazobactam for the treatment of osteomyelitis caused by multidrug-resistant pathogens: a case series
Ceftolozane–tazobactam (CT) is a recently approved novel cephalosporin and β-lactamase inhibitor combination agent with in vitro activity against various Gram-positive and Gram-negative pathogens, including several multidrug-resistant (MDR) Gram-negative organisms. CT is currently approved by the US...
Enregistré dans:
| Publié dans: | Ther Adv Drug Saf |
|---|---|
| Auteurs principaux: | , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
SAGE Publications
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6614941/ https://ncbi.nlm.nih.gov/pubmed/31312424 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2042098619862083 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|